IBIS-CT: Identification of Biomarkers in Ischemic Stroke - Clinical Trial

Sponsor
University Hospital, Brest (Other)
Overall Status
Recruiting
CT.gov ID
NCT04253275
Collaborator
(none)
60
1
3
23.2
2.6

Study Details

Study Description

Brief Summary

The objective of the study is to determine RNA blood biomarker based on 9 genes already identified in experimental studies, whose expression would be significantly increased in patient with ischemic stroke compared to controls.

Condition or Disease Intervention/Treatment Phase
  • Genetic: blood samples
  • Diagnostic Test: MRI without injection
N/A

Detailed Description

This is a monocentric study. It's a case-control study with case being first-ever ischemic stroke and controls being healthy (stroke free) subject patients paired for age, sex and cardiovascular risk or hemorrhagic stroke paired for age and sex.

Patients are followed for one year. Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y. Microvesicles samples will be taken at inclusion, 7d and 3M.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Identification of Biomarkers in Ischemic Stroke - Clinical Trial
Actual Study Start Date :
Nov 24, 2020
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Ischemic stroke patients

Patients with ischemic stroke diagnosed on clinical presentation and cerebral imaging

Genetic: blood samples
Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls. Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls.

Other: hemorragic stroke patients

Patients with hemorragic stroke diagnosed on clinical presentation and cerebral imaging

Genetic: blood samples
Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls. Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls.

Other: healthy controls

Stroke-free

Genetic: blood samples
Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls. Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls.

Diagnostic Test: MRI without injection
MRI at inclusion for controls

Outcome Measures

Primary Outcome Measures

  1. Expression (measured in log2) of each 9 targeted genes identified less than 6 hours after inclusion [6 hours after inclusion]

    Each targeted genes will be measured by quantitative reverse transcription Polymerase Chain Reaction (rt-PCR)

Secondary Outcome Measures

  1. RNA level expression across time according growth of infarction measured at inclusion and at 3 months [inclusion and 3 months]

    Each targeted genes will be measured by quantitative rt-PCR

  2. RNA level expression across time according Rankin scale at three months dichotomized in good (≤ 2) and bad prognosis (> 3). [at 3 months]

    Each targeted genes will be measured by quantitative rt-PCR

  3. Targeted RNA level expression according mechanism of ischemic stroke [at 3 months]

    Each targeted RNA level expression of targeted genes will be measured by quantitative rt-PCR

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • For ischemic stroke :

  • Age > 18-year-old

  • Ischemic stroke diagnosed on clinical presentation and cerebral imaging (CT or MRI imaging)

  • Inclusion inferior to 6 hours from stroke onset

  • Initial NIHSS score > 0 at the time of clinical examination

  • Patients with multimodal imaging either through MRI or CT perfusion and supra-aortic vessels and intra-cerebral vessels (Willis circle) imaging <0

  • Procedure of signed consent in situation of emergency : consent of the patient if he has the possibility to sign or his representative if he is present

  • For hemorragic stroke :

  • Age > 18 year-old

  • Hemorrhagic stroke diagnosed on clinical presentation and cerebral imaging (CT or MRI imaging)

  • Inclusion inferior to 6 hours from stroke onset

  • Initial NIHSS score > 0 at the time of clinical examination

  • Hemorrhagic patients are paired for age and sex with ischemic patients

  • Procedure of signed consent in situation of emergency : consent of the patient if he has the possibility to sign or his representative if he is present

For healthy controls :
  • Age > 18 year-old

  • Stroke-free standardized questionnaire

  • Initial NIHSS score = 0

  • Rankin score = 0

  • High risk cardiovascular subjects

  • Controls are paired for age, sex and cardiovascular risk measured by a score (European Heart Score) with ischemic patients

Exclusion Criteria:
  • Not affiliated to social security

  • Patient under legal protection or deprived of liberty by a judicial or administrative decision

  • Patient whose follow-up will be impossible

  • Prior stroke

GROUP FOR ISCHEMIC STROKE :
  • Patients with TIA and a negative cerebral CT or MRI
GROUP FOR HEMORRAGIC STROKE :
  • Cerebral hemorrhage related to subarachnoid hemorrhage

  • Post-traumatic hemorrhage

  • Hemorrhagic transformation in patients with ischemic stroke

GROUP FOR HEALTHY CONTROLS :
  • Contraindication MRI

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHRU Brest Brest France

Sponsors and Collaborators

  • University Hospital, Brest

Investigators

  • Principal Investigator: Serge TIMSIT, Pr, serge.timsit@chu-brest.fr

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Brest
ClinicalTrials.gov Identifier:
NCT04253275
Other Study ID Numbers:
  • IBIS-CT (29BRC19.0268)
First Posted:
Feb 5, 2020
Last Update Posted:
Dec 9, 2020
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 9, 2020